financetom
Technology
financetom
/
Technology
/
eClinical Solutions and Hobson & Company Quantify Financial and Operational Value of a Clinical Data Intelligence Platform for Clinical Trials
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
eClinical Solutions and Hobson & Company Quantify Financial and Operational Value of a Clinical Data Intelligence Platform for Clinical Trials
May 7, 2026 6:19 AM

Bringing price transparency to clinical trial technology investment and return, company unveils ROI calculator for pharmaceutical companies and CROs

BOSTON--(BUSINESS WIRE)--

eClinical Solutions LLC, a global provider of digital clinical software and services, today announced the results of a collaboration with Hobson & Company, a research firm specializing in Return on Investment (ROI) studies, to test and confirm the sources of value generated by the elluminate® Clinical Data Intelligence Platform, the company’s comprehensive AI-powered clinical data and analytics solution. Based on in-depth interviews with eClinical Solutions clients, the research examined how the technology can deliver measurable results and business benefits at a time when the growing volume of data and sources presents challenges for data management, medical monitoring, and trial operations teams, leading to extended cycle times.

Without a unified, modern clinical data infrastructure, teams are devoting significant time to data aggregation, report generation for safety reviews, data review, and raising queries. The research verified benefits of eClinical Solutions’ elluminate platform in three key areas: modernizing data infrastructure & analytics, streamlining clinical & data operations, and improving speed & quality of clinical trials.

The results - measured based on each organization's active studies, data aggregation, data review, queries, and issues, as well as timing from last patient last visit (LPLV) to database lock - include:

Modernize Data Infrastructure & Analytics:

90% reduction in time spent on data aggregation from multiple disparate systems

75% less time creating reports, listing, and data quality checks per new study

80% reduction in number of internal systems and vendor/CRO support agreements needed

Streamline Clinical & Data Operations:

30% less time spent gathering data for monitoring trial progress/oversight

25% reduction in time spent by medical monitors on medical data review and issue management

45% reduction in time spent by data managers on data review, queries, and issue management

Improve Speed & Quality of Clinical Trials:

25% reduction in cycle time from last patient last visit (LPLV) to database lock

1-3 weeks increase in the number of weeks in market, per study, due to reduced cycle times/trial delays

In a specific example, a total investment of $5.0M over three years in elluminate had a payback period of 4.6 months and the three-year total value created and return on investment were strong at $17.2M and 241% respectively. The sample organization was based on an average of 40 active studies/year with 12 new study starts per year, and pre-elluminate was spending: 8 hours/study/week on data aggregation; 20 hours/study/month gathering data for monitoring trial progress and oversight; 40 hours/study/month by medical monitors on medical data review and issue management; 120 hours/study/month by data managers on data review, queries, and issue management; and 6 weeks getting from LPLV to database lock.

As cycle times become the new currency of drug development, the company has created a web-based value calculator for life science leaders to understand the immediate and demonstrable benefits of the platform based on specific trial processes. The self-guided calculator is backed by proven research and provides leaders with a report and value estimate informed by industry benchmarks.

“With our AI-first approach across the end-to-end clinical research lifecycle - including the recent announcement of our elluminate AI agents - eClinical Solutions is constantly working to reduce manual burdens, improve efficiency, and help study teams reduce cycle times to bring treatments to patients faster,” said Raj Indupuri, CEO and co-founder of eClinical Solutions. “We have delivered tangible ROI for our existing clients and are now positioned to demonstrate to other industry sponsors how the elluminate Clinical Data Intelligence Platform can be implemented to achieve operational and financial gains.”

To read the full white paper produced by eClinical Solutions and Hobson & Company and for more information on the ROI current clients are seeing, visit this website. To learn how elluminate can provide measurable results for your organization, reduce timelines, and help bring drugs to regulatory review and market faster, visit the biopharma and CRO value calculator tools here.

About eClinical Solutions LLC

eClinical Solutions’ industry-leading clinical data intelligence platform, elluminate®, and biometrics services experts help biopharma researchers at large, mid-size, and emerging life sciences organizations develop tomorrow’s breakthroughs with today’s resources. eClinical is a privately-held, purpose-driven company with a global workforce and winner of the 2025 Top Workplace USA Award: Remote Work, the 2025 Top Workplaces Culture Excellence Award: Work-Life Flexibility, and Great Place To Work® India Certification™. Learn more at https://www.eclinicalsol.com/ and follow eClinical Solutions on LinkedIn.

Source: eClinical Solutions LLC

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Assessing Atlassian: Insights From 24 Financial Analysts
Assessing Atlassian: Insights From 24 Financial Analysts
Mar 19, 2025
Across the recent three months, 24 analysts have shared their insights on Atlassian ( TEAM ) , expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...
Activist Investor Starboard Targets Autodesk's Board With Proxy Battle - Report
Activist Investor Starboard Targets Autodesk's Board With Proxy Battle - Report
Mar 19, 2025
Activist investor Starboard Value is gearing up for a proxy fight with Autodesk Inc. ( ADSK ) , seeking to impact the composition of the design software company's board of directors. Holding a stake of over $500 million, Starboard intends to propose its own list of candidates at Autodesk’s forthcoming 2025 annual meeting. The activist investor raised concerns about Autodesk’s...
23 Analysts Have This To Say About Klaviyo
23 Analysts Have This To Say About Klaviyo
Mar 19, 2025
Klaviyo ( KVYO ) has been analyzed by 23 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings...
Intel's Options: A Look at What the Big Money is Thinking
Intel's Options: A Look at What the Big Money is Thinking
Mar 19, 2025
Financial giants have made a conspicuous bullish move on Intel ( INTC ). Our analysis of options history for Intel ( INTC ) revealed 10 unusual trades. Delving into the details, we found 50% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $417,589, and 2...
Copyright 2023-2026 - www.financetom.com All Rights Reserved